癌症研究泰斗Cell等三篇论文撤稿

2015-03-23 何嫱 生物通

Robert A.Weinberg身上笼罩着一道道绚丽的光环:美国科学院院士,世界著名的Whitehead研究所创始人之一,他曾发现了第一个人类癌基因Ras和第一个抑癌基因Rb,他的一系列杰出研究工作已经成为肿瘤研究领域乃至整个医学生物学领域的重要里程碑。Weinberg是是世界上论文被引用最多的科学家之一,他至少有20篇论文引用次数达上千次。近日,Weinberg和同事们宣布撤回了分别于2009

Robert A.Weinberg身上笼罩着一道道绚丽的光环:美国科学院院士,世界著名的Whitehead研究所创始人之一,他曾发现了第一个人类癌基因Ras和第一个抑癌基因Rb,他的一系列杰出研究工作已经成为肿瘤研究领域乃至整个医学生物学领域的重要里程碑。Weinberg是是世界上论文被引用最多的科学家之一,他至少有20篇论文引用次数达上千次。

近日,Weinberg和同事们宣布撤回了分别于2009年和2011年发表在 Genes & Development 杂志上的两篇论文,这两篇论文与Weinberg发表在2009年《细胞》(Cell)杂志上的另一篇论文有着直接的渊源。

三篇论文均探讨了一种叫做miR-31的microRNA在乳腺癌转移中的作用。2011年的这篇Genes & Development论文已被引用78次,发表在同一期刊的那篇2009年论文已被引用96次。
而根据最新的消息,Cell杂志的发言人已证实已引用达480次的这篇Cell研究论文也将被撤回:“此刻,我只能证实被 Genes & Development 引用的这篇论文正在撤稿,Cell即将发布官方的通告。”

根据 Genes & Development 杂志的撤稿通知,作者们表示:“我们的研究调查了miR-31调控乳腺癌转移不同方面的机制。我们将涉及miR-31的一篇较早期的论文(2009年)撤回,是因为为了能够组装图形面板汇编的数据来自于不同的复制实验。由于第二篇论文稿中使用的是相同的分析方法,我们认为撤回论文是一种负责任的做法。”

Weinberg在一封回复电子邮件中说:“我可以明确地告诉你,这些论文撤稿不会对我实验室当前以及过去的其他研究造成任何的影响。在我的实验室中其他人的研究工作并没有引用撤稿论文中所报道的研究结果,这些论文的撤稿无论如何不会影响我实验室发布的其他研究结果的解读。”
但Weinberg拒绝透露具体该由谁来对此负责。论文的第一作者Scott Valastyan已不在麻省理工学院任职,他的最后一篇研究论文发表于2012年。

这并非是Weinberg第一次撤回高影响的研究论文。2013年,Weinberg实验室撤回了发表在2004年《癌细胞》(Cancer cell)杂志上的一篇文章,理由是“论文中一些数据图像的加工/编译出现了错误。有一名叫做Yi-Ning Cheng的研究员没有在撤稿通知上签名,但撤稿通知声明科学家们相信尽管存在一些问题,论文的结论是可靠的。除了Weinberg这篇文章与新撤稿的论文没有任何的共同作者。

Weinberg表示,所有这些研究都进行了重复,当以正确的方法重做实验时研究结果是确定的。其中一篇论文将补充进新的支持数据重新发表。

涉及论文:

Valastyan S1, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA.A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis.Cell. 2009 Jun 12;137(6):1032-46. doi: 10.1016/j.cell.2009.03.047.
Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA.Activation of miR-31 function in already-established metastases elicits metastatic regression.Genes Dev. 2015 Mar 15;29(6):686.2.

Valastyan S, Benaich N, Chang A, Reinhardt F, Weinberg RA.Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis.Genes Dev. 2015 Mar 15;29(6):686.1.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959303, encodeId=dfb51959303d6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 28 12:12:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869052, encodeId=a51d186905227, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri May 08 04:12:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481170, encodeId=090414811e0b6, content=<a href='/topic/show?id=bada91402e3' target=_blank style='color:#2F92EE;'>#论文撤稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91402, encryptionId=bada91402e3, topicName=论文撤稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7277737197, createdName=644982816_68283323, createdTime=Wed Mar 25 06:12:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514134, encodeId=8e761514134fe, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Mar 25 06:12:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18673, encodeId=80d3186e34c, content=Robert A.Weinberg这是大神, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Mar 23 20:03:00 CST 2015, time=2015-03-23, status=1, ipAttribution=)]
    2015-12-28 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959303, encodeId=dfb51959303d6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 28 12:12:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869052, encodeId=a51d186905227, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri May 08 04:12:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481170, encodeId=090414811e0b6, content=<a href='/topic/show?id=bada91402e3' target=_blank style='color:#2F92EE;'>#论文撤稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91402, encryptionId=bada91402e3, topicName=论文撤稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7277737197, createdName=644982816_68283323, createdTime=Wed Mar 25 06:12:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514134, encodeId=8e761514134fe, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Mar 25 06:12:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18673, encodeId=80d3186e34c, content=Robert A.Weinberg这是大神, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Mar 23 20:03:00 CST 2015, time=2015-03-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959303, encodeId=dfb51959303d6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 28 12:12:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869052, encodeId=a51d186905227, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri May 08 04:12:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481170, encodeId=090414811e0b6, content=<a href='/topic/show?id=bada91402e3' target=_blank style='color:#2F92EE;'>#论文撤稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91402, encryptionId=bada91402e3, topicName=论文撤稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7277737197, createdName=644982816_68283323, createdTime=Wed Mar 25 06:12:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514134, encodeId=8e761514134fe, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Mar 25 06:12:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18673, encodeId=80d3186e34c, content=Robert A.Weinberg这是大神, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Mar 23 20:03:00 CST 2015, time=2015-03-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959303, encodeId=dfb51959303d6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 28 12:12:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869052, encodeId=a51d186905227, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri May 08 04:12:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481170, encodeId=090414811e0b6, content=<a href='/topic/show?id=bada91402e3' target=_blank style='color:#2F92EE;'>#论文撤稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91402, encryptionId=bada91402e3, topicName=论文撤稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7277737197, createdName=644982816_68283323, createdTime=Wed Mar 25 06:12:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514134, encodeId=8e761514134fe, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Mar 25 06:12:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18673, encodeId=80d3186e34c, content=Robert A.Weinberg这是大神, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Mar 23 20:03:00 CST 2015, time=2015-03-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959303, encodeId=dfb51959303d6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Dec 28 12:12:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869052, encodeId=a51d186905227, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri May 08 04:12:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481170, encodeId=090414811e0b6, content=<a href='/topic/show?id=bada91402e3' target=_blank style='color:#2F92EE;'>#论文撤稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91402, encryptionId=bada91402e3, topicName=论文撤稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c7277737197, createdName=644982816_68283323, createdTime=Wed Mar 25 06:12:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514134, encodeId=8e761514134fe, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Wed Mar 25 06:12:00 CST 2015, time=2015-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=18673, encodeId=80d3186e34c, content=Robert A.Weinberg这是大神, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Mar 23 20:03:00 CST 2015, time=2015-03-23, status=1, ipAttribution=)]
    2015-03-23 lovetcm

    Robert A.Weinberg这是大神

    0

相关资讯

Cell 40周年:40位40岁以下科研新星

在四十周年庆之际,Cell杂志邀请了全球四十位四十岁以下的优秀生物学家,分享了他们的科学理念、人生哲学、研究时的苦与乐、以及他们在实验室以外的生活。 颜宁 Cell:什么问题激励着你们实验室? 颜宁:生命令人着迷。什么是生命?(现我把生命看作是将能量转变为信息的一个系统。)生命的起源是什么?现在的生命形式是否只有一个共同的祖先?尽管这些问题深深吸引着我,但我眼下并没有在解决这

Cell Stem Cell十大热点文章

Cell Stem Cell 杂志是2007年Cell出版社新增两名新成员之一(另外一个杂志是Cell Host & Microbe),这一杂志内容涵盖了从最基本的细胞和发育机制到医疗软件临床应用等整个干细胞生物学研究内容。这一杂志特别关注胚胎干细胞、组织特异性和癌症干细胞的最新成果。 Cell Stem Cell 自创刊以来就倍受关注,影响因子迅速提升,从0一冲至16.826,又达到

中国机构CNS月报(2014年11月)

自然系列期刊在2012年的论文统计显示,发文140篇论文的中国科学院超过日本东京大学排名亚洲机构第一位,这也是Nature Index统计以来中国科研机构首次排名第一,反映出中国顶尖科研机构在数量上领跑亚洲。据生物探索统计,2014年11月份中国科研机构在Nature、Cell和Science三大系列期刊的总发文量是62篇,比上月低10篇。

盘点:2014年Cell 杂志亮点研究成果

不知不觉,2014年马上就要过去了,迎接我们的将是崭新的2015年,2014年三大国际著名杂志Cell、Nature和Science(CNS)依然刊登了很多亮点耐人寻味的研究,本文中小编就盘点了2014年Cell杂志及其子刊发表的一些非常有意义的亮点研究。Cell及其子刊:[1] Cancer Cell:科学家发现新型抗癌小分子约翰霍普金斯大学科学家在培养细胞体系中发现一种小分子具有破坏癌细胞

2014年被引用次数更多的中国期刊

近期清华大学中国学术文献国际评价研究中心公布了最新我国出版的6400多种人文社科和科技期刊的国际被引频次。统计显示,2013年我国共有4021种科技期刊被引用过至少一次,被引文献为278235篇,总被引频次为467851次。 其中生物类期刊 Cell Research 独占鳌头,成为国际被引用次数最多,学术影响力最高的学术期刊,排在其后的是清华大学的 Nano Researc

Cell Rep:肠癌干细胞被调节引发肠癌的分子机理

近日,发表在国际杂志Cell Reports上的一篇研究论文中,来自美国桑福德-伯纳姆医学研究所(Sanford-Burnham Medical Research Institute)的研究人员通过研究发现了一种新型的精细干细胞信号通路,如果该通路被打断则会引发肠道肿瘤,相关研究或可帮助理解干细胞如何引发肿瘤,并且可以帮助研究人员寻找靶向作用干细胞的分子来抑制肠癌的发生、发展和复发。